Kornimate/medical-research-clean huggingface dataset:
effect of perioperative glycemia protocol on glycemic outcomes in diabetic patients undergoing abdominal surgery

Conditions: Hyperglycemia; Perioperative Complication

Summary: this study evaluated to the effects of a glycaemic control protocol directed by nurses during the perioperative period on glycaemic outcomes in diabetic patients undergoing major abdominal surgery. the study was conducted at the department of general surgery of a research and training hospital.the study included 47 patients who underwent elective major abdominal surgery between september 2017 and december 2018. the number of patients in the intervention and the control groups was 22 and 25, respectively. the glycemia control protocol will be used in the glycemia management of intervention group,routine glycemia management will be used in the control group.

the prevalence of diabetes among the surgical patient population is 10-15%, and surgical operations are administered to diabetic patients more frequently compared to non-diabetic patients. diabetes or hyperglycaemia in surgical patients increases mortality and morbidity rates during the perioperative period by 50% compared to non-diabetic patients. maintaining patient blood glucose (bg) levels of within the target range during the surgical period is crucial to prevent postoperative complications. the target bg level has been modified in line with recent scientific findings; institutions (such as the american diabetes association), have prepared new guidelines for the management of glycaemia in critically ill and surgical patients. insulin infusion is the most effective method to control glycaemia in patients with critical disease or in patients about to undergo major surgery. therefore, current guidelines recommend the use of reliable and practical glycaemia control protocols during insulin infusion. these protocols should be learnt by all members of the team that provide healthcare. existing studies suggest that glycaemic management protocols are effective methods to achieve the target bg range and decrease the prevalence of hyperglycaemia and hypoglycaemia in critically ill and major surgery patients in a reliable and effective way.

Eligibility criteria:
inclusion criteria; * patients were diagnosed with type 2 diabetes * patients planned to undergo elective major abdominal surgery exclusion criteria; * patients who had diabetes other than type 2 diabetes * patient who had a preoperative glycated haemoglobin a1c (hba1c) value of 8.5% or greater * patient planned to undergo surgery related to the pancreas

Keywords: perioperative glycaemic management nursing glycaemic protocol glycaemic management stress hyperglycaemia surgery and diabetes
postmarketing surveillance study for imojev® in republic of korea

Conditions: Japanese Encephalitis

Summary: the purpose of the study is to perform the re-examination of imojev® in routine clinical settings in accordance with the ministry of food and drug safety regulation. primary objective: * to describe the safety profile of the first dose of imojev® administered under routine health care visit as primary vaccination or as booster.

subjects aged 12 months of age and older and who are given study vaccine during routine health-care visits will be enrolled in the study. no study vaccine will be supplied or administered as part of this study, subjects will be monitored following routine vaccine administration in clinical settings.

Eligibility criteria:
inclusion criteria: * informed consent form signed by the subject (for subjects 19 years old and above) or the parent(s) or other legal representative (for subjects under 19 years of age) * receipt of the first dose of imojev® (on the day of inclusion) according to approved local insert paper. exclusion criteria: * participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or a medical procedure. * subjects who already participated in this study.

Keywords: japanese encephalitis imojev® japanese encephalitis chimeric virus vaccine
the improvement of pelvic exams for patients with chronic vulvovaginal conditions

Conditions: Pain

Summary: the purpose of this study is to investigate patients self-reported comfort levels during each section of the pelvic exam.

the purpose of this randomized controlled trial is to investigate the sequence in which physicians perform the pelvic exam, describe and compare self-reported comfort during each section of the pelvic exam and how comfort during the examinations related to quality of life, self-esteem, and sexual function in english speaking females at least 18 years of age with chronic vulvovaginal conditions.

Eligibility criteria:
inclusion criteria: * english speaking are able to read and write english are utilizing outpatient services and being seen for a first appointment at an outpatient vulvodynia center exclusion criteria: * non english speaking * patients who cannot read or write * those who are pregnant * those who do not have a chronic vulvovaginal condition * patients other than "new" patients * patients who would not otherwise need a speculum exam
rituximab/bendamustine + rituximab/cytarabine for mantle cell lymphoma

Conditions: Mantle Cell Lymphoma

Summary: mantle cell lymphoma (mcl) is not curable with conventional therapy. this study sought to improve upon standard of care in newly diagnosed, untreated mcl patients who were transplant-eligible using drugs already established as active in mcl. the combination of rituximab-bendamustine followed by rituximab-cytarabine (rb/rc) was expected to maximize pre-asct complete response (cr) rate compared to historical rates approximating 55% with tolerable toxicity.

this was a pii single-arm design to determine whether the regimen looked promising for further study. primary objective • to evaluate the efficacy of an alternating regimen of rituximab-bendamustine and rituximab-cytarabine (rb/rc) using the cr/cru rate. secondary objectives * to assess safety. * to estimate the rate of complete remission (cr), unconfirmed cr (cru), partial remission (pr), stable disease (sd) and progressive disease (pd). * to estimate the rate of successful stem cell mobilization after rb/rc in responding patients. * to estimate the proportion of patients who can successfully complete the regimen and proceed to autologous stem cell transplantation (asct). * to estimate the rate of neutrophil and platelet engraftment after asct. * to estimate the cr/cru and pr rate for patients with blastoid variant mcl. * to estimate the rate of minimal residual disease (mrd)-negativity at treatment completion.

Eligibility criteria:
inclusion criteria: * mandatory pathologic review of the diagnostic specimen(s) at brigham and women's hospital or massachusetts general hospital * measurable disease * candidate for asct exclusion criteria: * prior anti-lymphoma therapy * pregnant or breastfeeding * hypersensitivity to rituximab * uncontrolled intercurrent illness * receiving other study agents * hiv positive on combination antiretroviral therapy

Keywords: newly diagnosed
the effects of oc000459 on nasal mediators

Conditions: Allergic Rhinitis

Summary: this is the first proof of concept study for oc000459 and is undertaken to assess the effects of the compound on the development of inflammatory cytokines in a model (nasal allergen challenge model) that is validated and clinically safe and easy to conduct. oc000459 will be compared with placebo in the study. the study will be a randomised, double blind, placebo controlled, crossover evaluation of the effect of oc000459 on cytokine secretion induced by nasal allergen challenge. male subjects with a known history of allergic rhinitis and screening positive to allergen will be included. after dosing with oc000459 or placebo, nasal allergen challenge will be performed and measurements made in the nasal fluids. nasal symptom scores will also be recorded. safety parameters will be monitored throughout.


Eligibility criteria:
inclusion criteria: 1. males aged 18 to 50 years with a history of symptoms of grass pollen related allergic rhinitis within the previous two years. exclusion criteria: 1. medical conditions likely to affect the outcome of the study. 2 history of immunotherapy in the past 3 years or currently on an immunotherapy treatment course including inhaled or local corticosteroids in the past 28 days. 3. any infirmity, disability, or geographic location which, in the opinion of the principal investigator, would limit compliance with the protocol.

Keywords: allergic rhinitis
endometrial preparation by short course of letrozole before hysteroscopic removal of endocavitary lesions

Conditions: Myoma;Uterus

Summary: the aim of this study is to evaluate the effectiveness of short course of letrozole for endometrial preparation before hysteroscopic surgery for intracavitary lesions.

in the cycle subsequent to hysteroscopic identification of an endouteine pathology, patients who fitted with the inclusion criteria will be randomly divided into two groups; letrozole group (study group) and placebo group (control group). the randomization will be a stratified randomization with permuted blocking (the block size is randomly permuted among 2, 4, and 6) within each stratum. the only stratification variable will be by type of endouterine pathology. the randomization will be balanced (using a 1:1 treatment ratio) and will be carried out by a nurse through sealed, unlabeled, opaque envelopes containing computer-generated random numbers. the study will be double-blind (the participants, caregivers and investigators will be blinded to block size and group assignment). women in the letrozole group will be treated with letrozole (5 mg daily) for 10 days before hysteroscopic intervention while women in the placebo group will be treated with placebo for 10 days before hysteroscopic intervention in the early follicular phase of a natural cycle. in both groups, monopolar hysteroscopic surgery with glycine (1.5%) as uterine distension media will be used. precise records of the duration of each surgical procedure, from the insertion to the removal of the resectoscope will be done. measurements of inflow, outflow, and amount of distension liquid absorbed by the patient will be taken meticulously. intraoperative bleeding will be defined as "light" when bleeding does not interfere with surgery, "moderate" when bleeding required the coagulation of vessels, and "severe" when hemorrhage required immediate suspension of hysteroscopy. at the end of surgery, surgeon satisfaction with endometrial preparation using visual analogue scale (vas) and quality of visualization of the uterine cavity will be compared. postoperative complications will be defined as the appearance of any complications occurring from the termination of the surgery to discharge.

Eligibility criteria:
inclusion criteria: * patients with endouterine pathologies, identified by office diagnostic hysteroscopy during the early endometrial proliferative phase (cycle days 7 to 8) exclusion criteria: * presence of large submucous (type i, type ii) or endocavitary (type 0) fibroids (according to the european society of hysteroscopy classification of submucous fibroids) with a diameter exceeding 4 cm, for which preoperative treatment with gnrh agonists is indicated. * hormonal therapies in the previous 8 weeks (including the drug of the study). * uterine and/or concomitant adnexal pathologies (including malignancy) for which hysteroscopic surgery was not considered either safe or the method to resolve the problem. * cardiovascular, hepatic, or renal impairment. * allergy to letrozole.

Keywords: letrozole submucous myoma
a pilot study of imatinib mesylate in steroid refractory chronic graft versus host disease

Conditions: Graft vs Host Disease

Summary: to determine if subjects with steroid refractory cgvhd can tolerate imatinib mesylate and whether their cgvhd responds to imatinib mesylate.


Eligibility criteria:
inclusion criteria * chronic graft-vs-host disease (cgvhd) requiring systemic therapy occurring \> 100 days after hematopoietic cell transplant with either: 1. persistent steroid dependence defined as the inability to taper steroid treatment to less than 0.25 mg/kg/d prednisone or its equivalent for at least 3 months. 2. progression of cgvhd signs and symptoms on steroid therapy equivalent to prednisone 0.5 mg/kg/d for at least 1 month. * at least one of the following manifestations: 1. skin changes (rash, sclerosis, fasciitis, or ulceration). 2. abnormal eye wetness ≤ 5 mm as measured by schirmer's test. 3. oral mucosal changes (erythema, lichenoid changes, ulcers, or mucoceles). 4. thrombocytopenia (platelets \< 50,000/ul). 5. abnormal liver function testing defined as alkaline phosphatase, ast, alt, or total bilirubin \> upper limit of normal (uln). 6. bronchiolitis obliterans (diagnosed by a \> 5% annual decline in fev1 with the lowest post-transplant fev1/fvc \< 0.8 and an appropriate ct scan or lung biopsy). * has been on a fixed dose of steroids or a fixed dose of steroids and one other immunosuppressant (cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or extracorporeal photopheresis) for ≥ 30 days before starting imatinib. * life expectancy ≥ 6 months. * ability to understand and willingness to sign a written informed consent document. * karnofsky performance status ≥ 3 50% (appendix b). * at least 18 years of age. * if a female of reproductive potential (defined as having at least 1 menstrual period in the past 12 months), must have a negative pregnancy test performed ≤ 7 days before starting study drug. * if a female of reproductive potential, agrees to use contraception for the duration of the trial. * total bilirubin \< 1.5x uln. * aspartate transaminase (ast) \< 2.5 x uln. * alanine aminotransferase (alt) \< 2.5 x uln. * alkaline phosphatase \< 2.5 x uln. * absolute neutrophil count (anc) \> 500/ul (growth factor supplementation is allowed). * hematocrit \> 26% (transfusion support is allowed). * platelet count \> 20,000/ul. exclusion criteria * received another investigational agent ≤ 30 days before starting the study drug. * ongoing intercurrent illness such as an infection not responsive to antibiotics, antiviral medicines, or antifungal medicines. * progressive malignant disease. * secondary malignancy that has not been effectively treated within the past 5 years (except localized basal cell or squamous cell carcinoma). * imatinib intolerance or allergy. * participant is breast-feeding. * not willing to comply with treatment or response evaluation. * received an allogeneic cell product \[including donor lymphocyte infusion (dli) or hematopoietic cell boost\] ≤ 100 days before starting study drug. * steroid and/or immunosuppressant dose has changed ≤ 30 days before starting study drug.
study of the neuro-protective effect of granulocyte-colony stimulating factor on early stage parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this study is to evaluate the effectiveness of neuroprotection from granulocyte colony-stimulating factor on parkinson disease

parkinson's disease (pd) is the second most common neurodegenerative disease and the severity of pd still progress during the ensuing years. currently, there is no promising medical or surgical treatment to abrogate the disease deterioration. granulocyte colony-stimulating factor (g-csf), one of hematopoietic growth factors, has been routinely used for hematologic disorders and stem cell harvest from normal subject. g-csf also demonstrated neuroprotection for rodents pd model. we hypothesize g-csf will exert the effectiveness of neuroprotection for pd patients.

Eligibility criteria:
inclusion criteria: * hoehn \& yahr stage i\~iii * patients with idiopathic parkinson's disease(pd), who meet the united kingdom parkinson's disease society brain bank diagnostic criteria, with a good response to levodopa * the onset of pd symptoms must be occurred \> = 40 years of age (to exclude yopd), and the patient must have been diagnosed with idiopathic pd \> =40 years of age * patients may have symptoms of wearing off and/or levodopa induced dyskinesia * patients must rate between hoehn \& yahr stage i to iii, when in an off medication state * patients must in their optimal medication treatment state, and will not changing their medications within 3 months before and after enrollment exclusion criteria: * patients who are proved to be young onset parkinson's disease (yopd) and/or genetically related (e.g. parkin). * women of child-bearing potential, pregnant or lactating. * patients who are proved to have tumor growth and/or malignancy. * patients with a past (within one year) or present history of psychotic symptoms requiring anti- psychotic treatment. * patients with active symptoms of major depression with suicidal ideation or suicide attempt. * patients with previous brain surgery (including pallidotomy and deep brain stimulation). * patients with significant cognitive impairment ( mini-mental state examination, mmse \< 24). * patients who do not sign the inform consent,
attention training technique and mindful self-compassion

Conditions: Anxiety; Depression; Stress, Psychological

Summary: the design of the study is a randomized controlled trial. a total of 80 students with self-reported symptoms of stress/anxiety/depression will be invited to take part in a 3-session course consisting of either attention training or self-compassion/mindfulness based meditation. attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing. self-compassion involves not avoiding painful or distressing feelings. instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.


Eligibility criteria:
inclusion criteria: * self reported symptoms of stress/anxiety/depression exclusion criteria: -
autofluorescence detection of oral malignancies and database and biospecimen collection to identify biomarkers of head and neck tumor progression

Conditions: Oral Cancer

Summary: this research may help dentists or surgeons to better detect areas in the mouth that are either prone to cancer or are early cancers. the earlier the detection on cancer in the mouth, the better the chance that treatment or prevention can be more effective.


Eligibility criteria:
inclusion criteria: patients with a history of suspicious lesions or currant suspicious lesions: * no history of cis or hnscc * history of clinically suspicious oral/oral pharyngeal lesions. * over 21 years old * not actively under treatment for any other type of malignancy, except non-melanoma skin cancer (nmsc) * must be willing to sign consent, have afl screening with biopsies and sample collection, must be willing to complete a social and health history questionnaire patients with biopsy proven dysplasia, cis or hnscc prior to treatment: * patients with biopsy proven dysplasia, cis or hnscc without a prior history of an antineoplastic treatment, including chemo/radiation and photodynamic therapy * biopsy performed at an outside institution and referred for evaluation for treatment, or biopsied here at rpci and proceeding for further care. * over 21 years of age. * must be willing to sign consent, have afl screening with biopsies and sample collection, must be willing to complete a social and health history questionnaire patients with clinically treated cis or hnscc amd no evidence of disease (ned): * patients with prior history of hnscc, previously treated with either surgery alone or combination of therapy, including head and neck radiation, with or without chemotherapy and photodynamic therapy including at least 3 months following completion of definitive treatment. * over 21 years of age * must be willing to sign consent, have afl screening with biopsies and sample collection, must be willing to complete a social and health history questionnaire
the evaluation of pro/antioxidative profile and diagnostic parameters in the patients with pancreatic disease

Conditions: Acute Pancreatitis

Summary: the study aims to assess and analyze some selected antioxidants and laboratory parameters during hospitalization of the patients with acute pancreatitis. it will allow to better understanding of the mechanisms of disease and the development of better diagnostic, treatment and monitoring. it is an observational diagnostic study and does not involve any additional administration of medicinal substances, modification of treatment or dropping the use of routine methods of treatment of a disease. the study procedure includes detailed personal medical history as separate document like as a routine medical interview, and three times taking a small amount of venous blood (together about 15 ml), in the first, third, and seventh day of hospitalization (in the case of longer hospital treatment).


Eligibility criteria:
inclusion criteria: * the patients were classified into the group of patients with acute pancreatitis (ap) due to clinical symptoms (acute onset of a persistent, severe, epigastric pain with tenderness on palpation on physical examination), personal interview and clinical method used in the diagnosis of pancreatitis - laboratory tests (elevation in serum lipase or amylase to three times or greater than the upper limit of normal) and characteristic findings of acute pancreatitis on imaging (contrast-enhanced computed tomography (ct), magnetic resonance imaging (mri) or transabdominal ultrasonography). in patients with characteristic abdominal pain and elevation in serum lipase or amylase to three times or greater than the upper limit of normal, no imaging was required to establish the diagnosis of acute pancreatitis. in patients with abdominal pain that was not characteristic for acute pancreatitis or serum amylase or lipase levels that were less than three times the upper limit of normal, or in whom the diagnosis was uncertain, the investigators performed abdominal imaging with a contrast-enhanced abdominal ct scan to establish the diagnosis of acute pancreatitis and to exclude other causes of acute abdominal pain. in patients with severe contrast allergy or renal failure, the investigators performed an abdominal mri without gadolinium. * the volunteers classified as healthy based on the research conducted by clinicians of primary medical care (control group) exclusion criteria: * other accompanied diseases than acute pancreatitis (the patients groups) * individuals of the control group with diagnosed disease as well as alcohol and drugs abusers

Keywords: smoke acute pancreatitis pro/antioxidant status pro-inflammatory factors lipid profile exocrine functions of pancreas
improving adherence healthy lifestyle with a smartphone application based on adults with intellectual disabilities

Conditions: Intellectual Disability

Summary: aim: improve adherence to physical activity in people with intellectual disabilities with a smartphone application design: randomized controlled trial subjects of the study: people with intellectual disabilities in occupational center ( aspromanis) intervention: data analysis: descriptive statistics, measuring central tendency and dispersion of the variables study. inferential statistics will be made between intervention of key variables and outcome


Eligibility criteria:
inclusion criteria: * participants were can write and read to ask scales * participant were able to use an smartphone exclusion criteria: * physical illness that prevent physical activity

Keywords: intellectual disability mhealth app physical activity adherence